ArticleEJHaem2023

A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States.

Anthony Mato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.